Acadian Asset Management
HOWL icon

Acadian Asset Management’s Werewolf Therapeutics HOWL Stock Holding History

Acadian Asset Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$291K Buy
+316,672
New +$201K ﹤0.01% 1540
2025
Q4 		– Sell
-34,285
Closed -$67K – 2034
2025
Q3 		$67K Sell
34,285
-26,992
-44% -$37K ﹤0.01% 1598
2025
Q2 		$66K Sell
61,277
-189,399
-76% -$195K ﹤0.01% 1452
2025
Q1 		$242K Buy
250,676
+8,412
+3% +$11K ﹤0.01% 1224
2024
Q4 		$358K Sell
242,264
-23,095
-9% -$47.1K ﹤0.01% 1152
2024
Q3 		$561K Buy
265,359
+53,063
+25% +$121K ﹤0.01% 1057
2024
Q2 		$516K Buy
212,296
+39,413
+23% +$189K ﹤0.01% 1190
2024
Q1 		$1.12M Buy
172,883
+94,212
+120% +$549K ﹤0.01% 811
2023
Q4 		$303K Hold
78,671
– – ﹤0.01% 1143
2023
Q3 		$167K Hold
78,671
– – ﹤0.01% 1226
2023
Q2 		$238K Hold
78,671
– – ﹤0.01% 1236
2023
Q1 		$203K Buy
78,671
+49,170
+167% +$147K ﹤0.01% 1253
2022
Q4 		$60K Buy
+29,501
New +$77.2K ﹤0.01% 1545

Other funds holding HOWL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
DF
DC Funds Mclean, Virginia $741K AUM 2.77% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Covestor
Covestor London, United Kingdom $157M AUM 35.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Acadian Asset Management's HOWL Position: Q3 2026 in Review

Acadian Asset Management opened a new position in Werewolf Therapeutics (HOWL) in Q3 2026: 316,672 shares worth $291K. The stake represents ﹤0.01% of the portfolio and ranks #1540 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in HOWL as recently as Q3 2025.

Acadian Asset Management first reported a position in HOWL in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.12M in Q1 2024. 30 funds tracked by Wall St. Rank hold HOWL as of Q3 2026.

  • Acadian Asset Management held 316,672 shares of Werewolf Therapeutics worth $291K as of Q3 2026.
  • Werewolf Therapeutics was a new Acadian Asset Management position in Q3 2026.
  • Werewolf Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q3 2026, its #1540 holding.
  • Acadian Asset Management first reported a position in Werewolf Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • Acadian Asset Management's Werewolf Therapeutics position peaked at $1.12M in Q1 2024.
  • 30 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2026.

Based on Acadian Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.